Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Birth Defects Res A Clin Mol Teratol ; 94(10): 790-803, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22991331

ABSTRACT

BACKGROUND: Fumonisin B(1) (FB(1)) is a mycotoxin produced by a common fungal contaminant of corn. Ingestion of FB(1)-contaminated food is associated with increased risk for neural tube defects (NTDs). FB(1) induces NTDs in inbred LM/Bc mice. FB(1) inhibits ceramide synthase in de novo sphingolipid biosynthesis, resulting in accumulation of sphinganine and sphinganine-1-phosphate (Sa1P). Sa1P functions as a ligand for a family of G protein-coupled S1P receptors. METHODS: Pregnant SWV and LM/Bc mice were treated with FB(1) (20 mg/kg/day intraperitoneally on embryonic day (ED) 7.5-8.5) or the known S1P receptor agonist FTY720 (10 mg/kg/day oral gavage on ED 6.5-8.5). LC/MS was used to detect sphingoid base-1-phosphates in maternal blood spots, plasma, and embryonic tissue. Strain-specific SWV and LM/Bc mouse embryonic fibroblasts (MEFs) and serum free mouse embryo (SFME) neural progenitor cells were treated with FB(1) (40 µM for 24 hr) and LC/MS was used to detect sphingoid base-1-phosphates. RESULTS: FTY720 induced NTDs in both the SWV and the LM/Bc strains of mice. Sphinganine-1-P (Sa1P) and FTY720-P were elevated in the blood spots and plasma of mice treated with FB(1) or FTY720, respectively. FTY720-P was elevated in ED 9.5 exencephalic embryos. Sa1P was elevated in SFME and MEF cells treated with FB(1), and Sa1P was higher in MEFs generated from the FB(1)-NTD-susceptible LM/Bc strain. CONCLUSIONS: Elevated sphingoid base-1-P after FB(1) or FTY720 suggest a potential role for these bioactive lipid ligands and activation of S1P receptor signaling pathways in the failure of neural tube closure after FB(1) or FTY720. Sa1P may represent a biomarker for FB(1)-NTD risk assessment.


Subject(s)
Fumonisins/adverse effects , Neural Tube Defects/chemically induced , Propylene Glycols/adverse effects , Sphingosine/analogs & derivatives , Animals , Cells, Cultured , Embryo, Mammalian , Female , Fingolimod Hydrochloride , Fumonisins/pharmacology , Mice , Mice, Inbred Strains , Models, Biological , Neural Tube Defects/pathology , Pregnancy , Prenatal Exposure Delayed Effects/blood , Prenatal Exposure Delayed Effects/chemically induced , Propylene Glycols/pharmacology , Sphingosine/adverse effects , Sphingosine/blood , Sphingosine/pharmacology , Up-Regulation/drug effects
2.
Birth Defects Res A Clin Mol Teratol ; 82(7): 494-507, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18383508

ABSTRACT

BACKGROUND: The reduced folate carrier (RFC1) is a ubiquitously expressed integral membrane protein that mediates delivery of 5-methyltetrahydrofolate into mammalian cells. In this study, embryonic/fetal development is characterized in an RFC1 knockout mouse model in which pregnant dams receive different levels of folate supplementation. METHODS: RFC1(+/-) males were mated to RFC1(+/-) females, and pregnant dams were treated with vehicle (control) or folic acid (25 or 50 mg/kg) by daily subcutaneous injection (0.1 mL/10 g bwt), beginning on E0.5 and continuing throughout gestation until the time of sacrifice. RESULTS: Without maternal folate supplementation, RFC1 nullizygous embryos die shortly postimplantation. Supplementation of pregnant dams with 25 mg/kg/day folic acid prolongs survival of mutant embryos until E9.5-E10.5, but they are developmentally delayed relative to wild-type littermates, display a marked absence of erythropoiesis, severe neural tube and limb bud defects, and failure of chorioallantoic fusion. Fgfr2 protein levels are significantly reduced or absent in the extraembryonic membranes of RFC1 nullizygous embryos. Maternal folate supplementation with 50 mg/kg/day results in survival of 22% of RFC1 mutants to E18.5, but they develop with multiple malformations of the eyelids, lungs, heart, and skin. CONCLUSIONS: High doses of daily maternal folate supplementation during embryonic/fetal development are necessary for early postimplantation embryonic viability of RFC1 nullizygous embryos, and play a critical role in chorioallantoic fusion, erythropoiesis, and proper development of the neural tube, limbs, lungs, heart, and skin.


Subject(s)
Dietary Supplements , Embryo, Mammalian/drug effects , Embryonic Development/drug effects , Folic Acid/pharmacology , Membrane Transport Proteins/genetics , Abnormalities, Multiple/epidemiology , Abnormalities, Multiple/etiology , Animals , Chorioallantoic Membrane/drug effects , Chorioallantoic Membrane/physiology , Embryo, Mammalian/physiology , Erythropoiesis/drug effects , Erythropoiesis/physiology , Female , Folic Acid/administration & dosage , Folic Acid Deficiency , Mice , Mice, Knockout , Pregnancy , Reduced Folate Carrier Protein
3.
BMC Genomics ; 9: 156, 2008 Apr 09.
Article in English | MEDLINE | ID: mdl-18400109

ABSTRACT

BACKGROUND: The reduced folate carrier (RFC1) is an integral membrane protein and facilitative anion exchanger that mediates delivery of 5-methyltetrahydrofolate into mammalian cells. Adequate maternal-fetal transport of folate is necessary for normal embryogenesis. Targeted inactivation of the murine RFC1 gene results in post-implantation embryolethality, but daily folic acid supplementation of pregnant dams prolongs survival of homozygous embryos until mid-gestation. At E10.5 RFC1-/- embryos are developmentally delayed relative to wildtype littermates, have multiple malformations, including neural tube defects, and die due to failure of chorioallantoic fusion. The mesoderm is sparse and disorganized, and there is a marked absence of erythrocytes in yolk sac blood islands. The identification of alterations in gene expression and signaling pathways involved in the observed dysmorphology following inactivation of RFC1-mediated folate transport are the focus of this investigation. RESULTS: Affymetrix microarray analysis of the relative gene expression profiles in whole E9.5 RFC1-/- vs. RFC1+/+ embryos identified 200 known genes that were differentially expressed. Major ontology groups included transcription factors (13.04%), and genes involved in transport functions (ion, lipid, carbohydrate) (11.37%). Genes that code for receptors, ligands and interacting proteins in the cubilin-megalin multiligand endocytic receptor complex accounted for 9.36% of the total, followed closely by several genes involved in hematopoiesis (8.03%). The most highly significant gene network identified by Ingenuitytrade mark Pathway analysis included 12 genes in the cubilin-megalin multiligand endocytic receptor complex. Altered expression of these genes was validated by quantitative RT-PCR, and immunohistochemical analysis demonstrated that megalin protein expression disappeared from the visceral yolk sac of RFC1-/- embryos, while cubilin protein was widely misexpressed. CONCLUSION: Inactivation of RFC1 impacts the expression of several ligands and interacting proteins in the cubilin-amnionless-megalin complex that are involved in the maternal-fetal transport of folate and other nutrients, lipids and morphogens such as sonic hedgehog (Shh) and retinoids that play critical roles in normal embryogenesis.


Subject(s)
Embryonic Development , Low Density Lipoprotein Receptor-Related Protein-2/metabolism , Maternal-Fetal Exchange , Receptors, Cell Surface/metabolism , Replication Protein C/metabolism , Transcription Factors/metabolism , Animals , Embryo, Mammalian/metabolism , Endocytosis , Female , Gene Regulatory Networks , Low Density Lipoprotein Receptor-Related Protein-2/chemistry , Membrane Proteins/chemistry , Membrane Proteins/metabolism , Mice , Mice, Knockout , Models, Molecular , Oligonucleotide Array Sequence Analysis , Polymerase Chain Reaction , Pregnancy , Receptors, Cell Surface/chemistry , Replication Protein C/genetics , Transcription Factors/genetics
4.
Birth Defects Res A Clin Mol Teratol ; 73(7): 487-97, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15959874

ABSTRACT

BACKGROUND: Fumonisin B1 (FB1) is a mycotoxin produced by the fungus Fusarium verticillioides, a common contaminant of corn worldwide. FB1 disrupts sphingolipid biosynthesis by inhibiting the enzyme ceramide synthase, resulting in an elevation of free sphingoid bases and depletion of downstream glycosphingolipids. A relationship between maternal ingestion of FB1-contaminated corn during early pregnancy and increased risk for neural tube defects (NTDs) has recently been proposed in human populations around the world where corn is a dietary staple. The current studies provide an in vivo mouse model of FB1 teratogenicity. METHODS: Pregnant LM/Bc mice were injected with increasing doses of FB1 on GD 7.5 and 8.5, and exposed fetuses were examined for malformations. Sphingolipid profiles and (3)H-folate concentrations were measured in maternal and fetal tissues. Immunohistochemical expression of the GPI-anchored folate receptor (Folbp1) and its association with the lipid raft component, ganglioside GM1, were characterized. Rescue experiments were performed with maternal folate supplementation or administration of gangliosides. RESULTS: Maternal FB1 administration (20 mg/kg of body weight) during early gestation resulted in 79% NTDs in exposed fetuses. Sphingolipid profiles were significantly altered in maternal and embryonic tissues following exposure, and (3)H-folate levels and immunohistochemical expression of Folbp1 were reduced. Maternal folate supplementation partially rescued the NTD phenotype, whereas GM1 significantly restored folate concentrations and afforded almost complete protection against FB1-induced NTDs. CONCLUSIONS: Maternal FB1 exposure altered sphingolipid metabolism and folate concentrations in LM/Bc mice, resulting in a dose-dependent increase in NTDs that could be prevented when adequate folate levels were maintained.


Subject(s)
Fumonisins/toxicity , Neural Tube Defects/chemically induced , Pregnancy, Animal , Animals , Carrier Proteins/metabolism , Dose-Response Relationship, Drug , Female , Folate Receptors, GPI-Anchored , Folic Acid/metabolism , Folic Acid/therapeutic use , G(M1) Ganglioside/antagonists & inhibitors , G(M1) Ganglioside/metabolism , G(M1) Ganglioside/pharmacology , Immunohistochemistry , Male , Maternal-Fetal Exchange , Mice , Mycotoxins/toxicity , Neural Tube Defects/prevention & control , Placenta/metabolism , Pregnancy , Receptors, Cell Surface/metabolism , Sphingolipids/chemistry , Sphingolipids/metabolism , Sphingosine/analogs & derivatives , Sphingosine/chemistry , Sphingosine/metabolism , Teratogens/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL
...